

Tokyo, Japan, September 21, 2022 – Teijin Limited has made the following personnel changes effective as of October 1, 2022.

New Position	Current Position	Name
Executive Officer, Member of the Board Chief Officer (Corporate Strategy)	Executive Officer, Member of the Board President, Healthcare Business of Teijin Group	Naohiko Moriyama
Teijin Group Executive Officer President, Healthcare Business of Teijin Group President, Teijin Pharma Limited	Teijin Group Executive Officer Management Coordinator for the President, Healthcare Business of Teijin Group (for Teijin Pharma) President, Teijin Pharma Limited	Ichiro Watanabe
Teijin Group Corporate Officer Senior Managing Director - Teijin Pharma Limited Deputy President, Teijin Pharma Limited	Teijin Group Corporate Officer Senior Managing Director - Teijin Pharma Limited General Manager, Research, Development & Technology Unit	Kenichiro Kataoka
Teijin Group Corporate Officer General Manager, Composites Business Unit	Teijin Group Corporate Officer Chief Officer (Corporate Strategy)	Masataka Akiyoshi
Teijin Group Corporate Officer Managing Director - Teijin Pharma Limited General Manager, Research, Development & Technology Unit	Teijin Group Corporate Officer General Manager, Healthcare Planning & Control Division Managing Director - Teijin Pharma Limited General Manager, Planning & Control Division	Masaki Taneda
Scheduled to retire (Dated September 30, 2022)	Teijin Group Corporate Officer General Manager, Composites Business Unit	Steve Rooney

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement "Human Chemistry, Human Solutions," Teijin aims to be a company that supports the society of the future. The group comprises some 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2022.

Please visit www.teijin.com

Press Contact

Corporate Communications

Teijin Limited

+81 3 3506 4055

pr@teijin.co.jp